
Lisata Therapeutics, Inc.: A global biopharmaceutical firm focusing on cardiovascular and autoimmune diseases.
Lisata Therapeutics, Inc., founded in New York, is a global biopharmaceutical company dedicated to developing innovative therapies for cardiovascular and autoimmune diseases. The company's core mission is to address high unmet medical needs through targeted therapy and rigorous data application. Lisata's product offerings include the CendR Platform® Technology, which enhances the delivery of anti-cancer drugs to solid tumors and targets non-cancerous, immunosuppressive cells, thereby improving treatment efficacy.
Notable figures associated with Lisata Therapeutics include leading scientists and industry experts who contribute to its research and development efforts. The company has attracted significant investment from prominent venture capital firms, underscoring confidence in its potential. Key achievements include advancing multiple clinical-stage therapies and demonstrating promising results in early trials. Lisata's impact is reflected in its commitment to transforming patient outcomes through cutting-edge biopharmaceutical innovations.

Lusaris Therapeutics
lusaristx.com

Thetis Pharmaceuticals
thetispharma.com

Lyst Therapeutics

Lysosomal Therapeutics
lysosomaltx.com

Celsius Therapeutics
celsiustx.com

Astria Therapeutics
astriatx.com

Lapix Therapeutics
lapix.com

LTZ Therapeutics

LizarBio Therapeutics

Rise Therapeutics

Lassen Therapeutics

MapLight Therapeutics

Cardurion Pharmaceuticals

Cartesian Therapeutics

Lyra Therapeutics
Companies similar to Lisata Therapeutics include Lusaris Therapeutics, Thetis Pharmaceuticals, Lyst Therapeutics and Lysosomal Therapeutics.
Lisata Therapeutics was founded in 1980.
Lisata Therapeutics' headquarters is located in Basking Ridge, NJ, US.
Lisata Therapeutics' most recent funding round was for $1.4M (USD) in May 2021.
As of May 12, 2021, Lisata Therapeutics has raised a total of $165.6M (USD).
Lisata Therapeutics has 500 employees as of Feb 6, 2024.